Current Headlines

  1. LegoChem Biosciences Enters Into Research Licensing Agreement With Takeda To Develop Next-Generation Antibody-Drug Conjugate Candidates
    1/11/2017

    LegoChem Biosciences (“LCB”), based in Daejeon South Korea, announced recently that the Company has entered into a research licensing agreement with Takeda Pharmaceuticals Company Limited (”Takeda”) to evaluate next-generation antibody drug conjugate (ADC) candidates

  2. Lilly And Merck Expand Immuno-Oncology Collaboration
    1/11/2017

    Eli Lilly and Company (NYSE: LLY) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, through a subsidiary, to add a new study of Lilly's LARTRUVO™ (olaratumab) with KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS).

  3. Certara Launches Version 16 Of Its Simcyp Population-Based Simulator
    1/10/2017

    Certara, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, recently announced that it has released version 16 of its Simcyp Population-based Simulator

  4. Genervon Releases ALS, PD And AD Disease-Associated Gene Lists Modulated By GM6 And Encourages Researchers To Explore New Discoveries Beyond Single Target Drug Development Paradigm
    1/10/2017

    Genervon Biopharmaceuticals LLC ("Genervon") has published a confidential list of genes associated with Parkinson's disease (PD 46-59 genes, 2 to 1.5 folds, link: https://f1000research.com/posters/6-28) recently during the JP Morgan Healthcare Conference in San Francisco

  5. Icagen Announces Distribution Agreement With On Target For Advancing Early Drug Discovery In Japanese Market
    1/10/2017

    Drug discovery services and products provider Icagen, Inc. announced today an agreement with Japan-based drug discovery sales specialist On Target Co., Ltd. granting On Target Company, Ltd. rights to broker Icagen's products and services in this important territory

  6. G1 Therapeutics Initiates Three Drug Development Programs In Breast Cancer
    1/10/2017

    G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the expansion of its pipeline of novel cancer therapies with the initiation of three development programs in breast cancer. G1 is enrolling a Phase 2 study of its intravenous CDK4/6 inhibitor trilaciclib for the treatment of triple-negative breast cancer (TNBC), and a Phase 1b/2a study of its oral CDK4/6 inhibitor G1T38 for the treatment of estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. In addition, G1 is advancing G1T48, its oral selective estrogen receptor degrader (SERD) with the goal of commencing a Phase 1 trial in the fourth quarter of 2017.

  7. Quanterix’ Momentum Fuels Vision For The Future Of Precision Health
    1/9/2017

    Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, recently announced significant milestones that are shaping the future of the company’s technology, driving global expansion of its customer and partner portfolio, and fueling research that advances the science of precision health

  8. Zebra Biologics Inc. To Collaborate With AbbVie To Discover New Antibody Therapeutics.
    1/9/2017

    Zebra Biologics Inc., an emerging pre-clinical stage biotechnology company, recently announced that the company has entered into a collaboration with AbbVie to discover agonist antibody therapeutics for inflammatory diseases

  9. Ferring Partners With Intralytix To Develop Bacteriophage Treatments For Conditions Associated With The Microbiome And Drug-Resistant Bacteria
    1/9/2017

    Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome

  10. Enanta Announces High SVR12 Rates Achieved In Genotype 1 Chronic HCV Infected Japanese Patients With Eight Weeks Of Treatment With AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P)
    1/9/2017

    Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced results from AbbVie’s Phase 3 CERTAIN-1 study of 8 weeks of treatment with AbbVie’s investigational, pan-genotypic, ribavirin (RBV)-free regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in Japanese patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection without cirrhosis